Atmo Biosciences gas capsule receives FDA clearance
Posted: 30 June 2025 Atmo Biosciences has been granted clearance by the United States Food and Drug Administration (FDA) under the 510(k) process for its Atmo Gas Capsule System, enabling its first product to be marketed and sold…
Noxopharm advances HERACLES clinical trial recruitment
Posted: 30 June 2025 Noxopharm Limited (ASX:NOX), a clinical-stage biotechnology firm, has announced rapid progress in the recruitment phase of its HERACLES clinical trial, staying on track with its timeline. HERACLES is a groundbreaking first-in-human study for SOF-SKN™,…
CSL’s Andembry™ wins FDA Approval as first-of-its-kind monthly preventative for Hereditary Angioedema
Posted: 23 June 2025 CSL announced that its novel monoclonal antibody therapy, Andembry™ (garadacimab-gxii), had been granted approval by the U.S. Food and Drug Administration (FDA) for the prevention of HAE attacks in patients aged 12 and older.…
Inoviq’s new Cancer treatments kills 88% of Breast and Lung Cancer Cells in lab tests
Posted: 23 June 2025 INOVIQ Limited announced that a significant milestone had been reached in its exosome-based therapeutic programme, with laboratory studies confirming the treatment’s potent activity against two aggressive cancer types. The preclinical candidate, utilising CAR-NK-derived extracellular…
Wavewise Analytics awarded $996,995 in funding through TTRA initiative
Posted: 23 June 2025 Wavewise Analytics has been awarded $996,995 in funding through MTPConnect’s Targeted Translation Research Accelerator (TTRA) — an important initiative funded by the Australian Government’s Medical Research Future Fund (MRFF). This funding will accelerate the…
MTPConnect announces $12 million investment in Heart Disease and Diabetes innovations
Posted: 23 June 2025 A substantial investment of $12.07 million was announced by MTPConnect to support 14 domestic life science companies developing innovative medical devices and pharmaceuticals aimed at reducing the impact of cardiovascular disease and diabetes (types…
WEHI researchers announce breakthrough in Long COVID treatment
Posted: 23 June 2025 A groundbreaking study was conducted by scientists at the Walter and Eliza Hall Institute (WEHI), revealing a novel drug compound that prevented long COVID symptoms in mice. This landmark discovery was anticipated to pave…
Radium Capital unleashes $400m war chest for Aussie innovators
Posted: 13 June 2025 Radium Capital, Australia’s leader in R&D finance, has announced plans to lend $400 million to Australian innovators over the next 12 months. Radium Capital has deployed more than $900 million to companies undertaking research…
Telix Pharmaceuticals launches new Prostate Cancer Imaging Agent in U.S.
Posted: 13 June 2025 Telix Pharmaceuticals Limited announced that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), had become commercially available nationwide in the United States (U.S.). Kevin…
Chimeric Therapeutics Receives $2.5 Million Advance on FY25 R&D Tax Incentive
Posted: 12 June 2025 Chimeric Therapeutics Limited (ASX:CHM), an Australian leader in cell therapy, announced the receipt of $2,500,000 from Endpoints Capital under a funding facility secured against the anticipated FY25 Research and Development Tax Incentive (RDTI). The…
Peter MacCallum Cancer Centre Announces Promising Prostate Cancer Therapy Results
Posted: 11 June 2025 Peter MacCallum Cancer Centre revealed highly encouraging initial results from its groundbreaking Terbium-161 prostate cancer therapy. The findings were presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago and…
Chimeric Therapeutics’ CHM CDH17 Granted FDA Fast Track Designation
Posted: 10 June 2025 Chimeric Therapeutics (ASX:CHM) announced that the US Food and Drug Administration (FDA) had granted Fast Track Designation to CHM CDH17. This designation was based on the FDA’s assessment of CHM CDH17’s potential to improve…
